Related Experiment Video

Updated: May 31, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet agents for stroke prevention

Samuel Yip1, Oscar Benavente

  • 1Division of Neurology, Brain Research Centre, University of British Columbia, Stroke Program, Vancouver, British Columbia V5Z1M9, Canada. samyip100@gmail.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|July 16, 2011
PubMed

Insights

Antiplatelet agents are crucial for secondary stroke prevention in noncardioembolic stroke patients. Early, lifelong treatment with aspirin, clopidogrel, or aspirin/dipyridamole is recommended, as combination therapy has not shown proven benefits.

Area of Science:

  • Neurology
  • Cardiology
  • Vascular Medicine

Background:

  • Stroke is a major cause of death and disability.
  • Ischemic stroke has diverse causes and mechanisms.
  • Stroke survivors face a high risk of recurrent vascular events.

Purpose of the Study:

  • To review the role of antiplatelet agents in secondary stroke prevention.
  • To evaluate the efficacy and safety of different antiplatelet therapies.
  • To provide guidance on optimal antiplatelet treatment strategies after ischemic stroke.

Main Methods:

  • Review of available data on antiplatelet agents for stroke prevention.
  • Analysis of evidence for combination therapy (aspirin plus clopidogrel).
  • Comparison of different antiplatelet monotherapies (aspirin, clopidogrel, aspirin/dipyridamole).

Main Results:

  • Antiplatelet agents are fundamental for secondary stroke prevention in noncardioembolic stroke.
  • Combination therapy (aspirin plus clopidogrel) is not proven effective or safe for early or long-term prevention.
  • No single antiplatelet agent demonstrates superiority for specific stroke subtypes.

Conclusions:

  • Aspirin, clopidogrel, or aspirin with extended-release dipyridamole are valid options for secondary stroke prevention.
  • Treatment initiation should be as early as possible.
  • Lifelong treatment with antiplatelet agents is recommended to maximize benefits.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...